Palatin Technologies Stock Quote PTN - Stock Price, News, Charts, Message Board, Trades

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

0.92

Bid

Ask

Volume

101,997

0.91 Day's Range 0.9669

0.68 52 Week Range 5.65

Market Cap

17.984M

Previous Close

0.9142

Open

0.92

Last Trade

330

0.9385

Last Trade Time

16:10:00

Financial Volume

$ 95,197

VWAP

0.933335

Average Volume (3m)

282,149

Shares Outstanding

19,548,167

Dividend Yield

PE Ratio

-0.60

Earnings Per Share (EPS)

-1.52

Revenue

4.49M

Net Profit

-29.74M

Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its programs are based on molecules that modulate the activity of the me... Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its main product in clinical development is bremelanotide, which treats hypoactive sexual desire disorder, which is a type of female sexual dysfunction. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

palatin.com

Headquarters

Wilmington, Delaware, USA

Founded

Palatin Technologies Inc New is listed in the Pharmaceutical Preparations sector of the American Stock Exchange with ticker PTN. The last closing price for Palatin Technologies was $0.91. Over the last year, Palatin Technologies shares have traded in a share price range of $ 0.68 to $ 5.65.

Palatin Technologies currently has 19,548,167 shares outstanding. The market capitalization of Palatin Technologies is $17.87 million. Palatin Technologies has a price to earnings ratio (PE ratio) of -0.60.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results

Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results PR Newswire CRANBURY, N.J., Nov. 14, 2024 Obesity programs:Core focus on obesity includes exploratory co-administration...

Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024

Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024 PR Newswire CRANBURY, N.J., Nov. 8, 2024 CRANBURY, N.J., Nov. 8, 2024...

Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024

Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024 PR Newswire CRANBURY, N.J., Nov. 4, 2024 Oral PL7737 significantly...

Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity

Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity PR Newswire CRANBURY, N.J., Oct...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form EFFECT - Notice of Effectiveness

Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium

Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium PR Newswire CRANBURY, N.J., Oct. 24, 2024 Data...

Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium

Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium PR Newswire CRANBURY, N.J., Oct. 23, 2024 High...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.18	-16.3636363636	1.1	1.1	0.9	225181	0.97182355	CS
4	-0.18	-16.3636363636	1.1	1.4	0.9	261800	1.14995418	CS
12	-0.72	-43.9024390244	1.64	1.72	0.68	282149	1.06324929	CS
26	-1.15	-55.5555555556	2.07	2.13	0.68	192455	1.2618386	CS
52	-0.97	-51.3227513228	1.89	5.65	0.68	337838	2.2876241	CS
156	0.545	145.333333333	0.375	8.6	0.1811	1071670	0.85286914	CS
260	0.1294	16.3673159626	0.7906	8.6	0.1811	1567938	0.75411846	CS

Symbol	Price	Vol.
GPUSHyperscale Data Inc	$ 0.23 (30.76%)	609.65k
AIRIAir Industries Group	$ 4.65 (6.90%)	890
BTTRBetter Choice Company Inc	$ 1.79 (5.19%)	563
PLAGPlanet Green Holdings Corp	$ 3.30 (3.77%)	322
SLIStandard Lithium Ltd	$ 1.71 (3.01%)	2.8k
CPHIChina Pharma Holdings Inc	$ 0.1914 (-3.82%)	3.15k
LCTXLineage Cell Therapeutics Inc	$ 0.58 (-3.32%)	46.34k
MSTUT Rex 2X Long MSTR Daily Target ETF	$ 180.00 (-2.55%)	30.76k
BITQBitwise Crypto Industry Innovators Etf	$ 19.2035 (-2.52%)	1.62k
VTAKCatheter Precision Inc	$ 0.415 (-2.10%)	3.66k
MSTZT Rex 2X Inverse MSTR Daily Target ETF	$ 1.09 (0.93%)	3.8M
FXIiShares China Large Cap	$ 30.32 (-0.10%)	3.32M
XLFFinancial Select Sector	$ 50.17 (-0.01%)	2.31M
HYGiShares iBoxx Dollar High Yield Corporate Bond	$ 79.51 (0.03%)	2.22M
SOXLDirexion Daily Semiconductor Bull 3X Shares	$ 28.44 (-0.07%)	2.15M

Symbol

Price

Vol.

MSTZT Rex 2X Inverse MSTR Daily Target ETF

$ 1.09

(0.93%)

3.8M

FXIiShares China Large Cap

$ 30.32

(-0.10%)

3.32M

XLFFinancial Select Sector

$ 50.17

(-0.01%)

2.31M

HYGiShares iBoxx Dollar High Yield Corporate Bond

$ 79.51

(0.03%)

2.22M

SOXLDirexion Daily Semiconductor Bull 3X Shares

$ 28.44

(-0.07%)

2.15M

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Palatin Technologies Inc New (PTN)

Professional-Grade Tools, for Individual Investors.

Key stats and details

About Palatin Technologies Inc New

Ask ADVFN Intelligence (AI)

PTN Latest News